Arrowhead Pharmaceuticals NASDAQ: ARWR is preparing for a potential expansion of its recently launched drug REDEMPLO into severe hypertriglyceridemia, while advancing experimental treatments for mixed hyperlipidemia, neurological diseases and obesity-related conditions, CEO Chris Anzalone said at a Jefferies event.
Arrowhead filed a supplemental new drug application for REDEMPLO on Nov. 2 and expects a decision potentially in the March-April timeframe, Anzalone said. The drug is currently marketed for familial chylomicronemia syndrome, or FCS, a rare condition characterized by elevated triglycerides.
Anzalone said the application received STAR designation, which he described as a process that generally takes up to six months but aims for a shorter review. The company had not yet received a formal FDA decision date, he said.
REDEMPLO expansion and launch plans
Anzalone pointed to results from the Phase 3 SHASTA-3 and SHASTA-4 studies as support for the application. He said patients with severe hypertriglyceridemia experienced an approximately 80% reduction in triglycerides from baseline, alongside an improvement in rates of pancreatitis.
Among patients with triglycerides above 500 mg/dL and a history of pancreatitis, Anzalone said the number needed to treat was three over 12 months to prevent one episode of pancreatitis. Arrowhead is continuing SHASTA-5, a longer-term, event-driven study in high-risk patients, to gather additional evidence.
The CEO said Arrowhead expects REDEMPLO’s quarterly dosing and safety profile to differentiate it from Ionis’ TRYNGOLZA. Anzalone said Arrowhead does not expect REDEMPLO to require liver monitoring or dose titration for the proposed indication. The final label for that use remains subject to regulatory review.
Arrowhead estimates that 3 million to 3.5 million people in the U.S. have triglycerides above 500 mg/dL, including approximately 1 million whom it considers at particularly high risk. Anzalone said the company sees a potential $3 billion to $4 billion in annual peak U.S. sales, supported initially by that high-risk group. He cited a $45,000 annual list price and said the company is doing little discounting in FCS, though payer terms for severe hypertriglyceridemia remain to be seen.
Arrowhead is discussing coverage with payers before a potential launch and has largely built out its commercial team, Anzalone said. He cautioned against providing revenue guidance before the company better understands payer responses.
For the existing FCS launch, Anzalone said Arrowhead was receiving 50 to 60 new prescriptions a week and had approximately 160 million covered lives. Conversion from prescriptions to paid shipments has taken time as coverage policies are established, he said, adding that the company had made progress with payers in recent weeks. He expects continued prescription growth but not necessarily a sharp inflection before the potential expansion decision.
Pipeline updates
Arrowhead expects multiple-dose data for ARO-DIMER in the first half of 2027. The experimental treatment is designed to target both PCSK9, to lower LDL cholesterol, and APOC3, to lower triglycerides in patients with mixed hyperlipidemia.
Anzalone said early single-dose results showed similar LDL reduction to PCSK9 inhibitors and better reduction in ApoB, another marker the company is monitoring. He believes a potential registration study could rely on LDL reduction, though the company has not established the final study population.
For ARO-MAPT, an experimental RNA interference treatment designed to reduce tau, Anzalone said initial data showed proof of concept for delivery to the brain after a subcutaneous injection. Multiple-dose data in healthy volunteers are expected in the first half of 2027. He also said Arrowhead expects data from Alzheimer’s patients throughout 2027 and could potentially start a Phase 3 study in frontotemporal dementia toward the end of that year.
Arrowhead also plans to report more obesity-related data by year-end. Anzalone said its INHBE program is increasingly being explored for MASH after showing reductions in liver fat when combined with tirzepatide, while further ALK7 data could inform additional obesity studies in 2027.
Separately, Anzalone said the company expects to complete a Phase 3 study of zodasiran for homozygous familial hypercholesterolemia around the middle of 2027 and potentially file a new drug application by year-end.
About Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company's research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.
While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.